일 대학병원에서의 주요우울장애에서 비정형 항정신병약물 병합 요법의 우울증상 개선 효과 : 1년 추적 연구
The Effects of Adjuvant Therapy of Atypical Antipsychotics on the Change of Clinical Symptoms in Patients with Major Depressive Disorder in a University Hospital : 1 Year Follow-Up Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives This study is to assess the effects of adjuvant therapy of atypical antipsychotics on the change clinical symptoms in patients with major depressive disorder. Methods We conducted a chart review of patients, who visited a university hospital. Ninety seven patients were divided into two groups : patients with adjuvant use of antipsychotics with antidepressants (AD+AAP ; n=32) and patients with only antidepressants (AD ; n=65). We compared and analyzed three clinical domains including depressive symptoms, anxiety symptoms and sleep qualities between two groups. Depressive symptoms, Anxiety symptoms, and sleep pattern were evaluated by Beck’s Depression Inventory (BDI), Beck’s Anxiety Inventory (BAI), and Pittsburgh Sleep Quality Index (PSQI) at baseline (first day of admission) and 1 year later. Results During 1 year, the BDI scores of AD+AAP group has been greatly decreased, compared to AD group (F=5.87, p=0.02). In the comparison of patients with severe symptoms of major depressive disorder (BDI score >21), there was significant difference in the change of BDI score between AD+AAP and AD (F=4.14, p=0.04). After 1 year, there were no significant differences in BAI score change (F=0.51, p=0.47), PSQI score change (F=0.89, p=0.35) between two group. However, the duration of adjunctive therapy and the type of atypical antipsychotics would not impact the results. Conclusion Current study suggested that adjuvant therapy of atypical antipsychotics would be effective on depressive symptoms in patients with severe major depressive disorder, compared to the treatment with antidepressants alone.
Abstract
Objectives This study is to assess the effects of adjuvant therapy of atypical antipsychotics on the change clinical symptoms in patients with major depressive disorder. Methods We conducted a chart review of patients, who visited a university hospital. Ninety seven patients were divided into two groups : patients with adjuvant use of antipsychotics with antidepressants (AD+AAP ; n=32) and patients with only antidepressants (AD ; n=65). We compared and analyzed three clinical domains including depressive symptoms, anxiety symptoms and sleep qualities between two groups. Depressive symptoms, Anxiety symptoms, and sleep pattern were evaluated by Beck’s Depression Inventory (BDI), Beck’s Anxiety Inventory (BAI), and Pittsburgh Sleep Quality Index (PSQI) at baseline (first day of admission) and 1 year later. Results During 1 year, the BDI scores of AD+AAP group has been greatly decreased, compared to AD group (F=5.87, p=0.02). In the comparison of patients with severe symptoms of major depressive disorder (BDI score >21), there was significant difference in the change of BDI score between AD+AAP and AD (F=4.14, p=0.04). After 1 year, there were no significant differences in BAI score change (F=0.51, p=0.47), PSQI score change (F=0.89, p=0.35) between two group. However, the duration of adjunctive therapy and the type of atypical antipsychotics would not impact the results. Conclusion Current study suggested that adjuvant therapy of atypical antipsychotics would be effective on depressive symptoms in patients with severe major depressive disorder, compared to the treatment with antidepressants alone.
참고문헌 (29)
- 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
- Morilak DA, "Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders", Int J Neuropsychopharmacol, 7, pp.193~218 (2004)
- Hindmarch I, "Expanding the horizons of depression: beyond the monoamine hypothesis", Hum Psychopharmacol, 16, pp.203~218 (2001)
- Nelson JC, "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials", Am J Psychiatry, 166, pp.980~991 (2009)
- Nelson JC, "Augmentation strategies for treatment of unipolar major depression", Mod Probl Pharmacopsychiatry, 25, pp.34~55 (1997)
- Andreescu C, "Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features", J Clin Psychiatry, 68, pp.194~200 (2007)
- Meyers BS, "A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)", Arch Gen Psychiatry, 66, pp.838~847 (2009)
- Nelson JC, "Augmentation treatment in major depressive disorder: focus on aripiprazole", Neuropsychiatr Dis Treat, 4, pp.937~948 (2008)
- Ostroff RB, "Risperidone augmentation of selective serotonin reuptake inhibitors in major depression", J Clin Psychiatry, 60, pp.256~259 (1999)
- Shelton RC, "The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination", Ther Clin Risk Manag, 2, pp.187~192 (2006)
- Zhang W, "Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex", Neuropsychopharmacology, 23, pp.250~262 (2000)
- Tadori Y, "Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors", Eur J Pharmacol, 597, pp.27~33 (2008)
- Komossa K, "Second-generation antipsychotics for major depressive disorder and dysthymia", Cochrane Database Syst Rev, pp.008121~ (2010)
- Jensen NH, "N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity", Neuropsychopharmacology, 33, pp.2303~2312 (2008)
- Beck AT, "An inventory for measuring depression", Arch Gen Psychiatry, 4, pp.561~571 (1961)
- Han HM, "A standardization study of Beck Depression Inventory in Korea", J Korean Neuropsychiatr Assoc, 25(3), pp.487~500 (1986)
- Lee YH, "A study of the reliability and the validity of the BDI, SDS, and MMPI-D scales", Korean J Clin Psychol, 10, pp.98~113 (1991)
- Yook SP, "A clinical study on the Korean version of Beck Anxiety Inventory: comparative study of patient and non-patient", Korean J Psychol, 16, pp.185~197 (1997)
- 최영미, "새터민을 위한 PTSD 극복 프로그램 개발 및 효과 검증 예비 연구", 신경정신의학, 49(2), pp.248~255 (2010), 대한신경정신의학회
- Buysse DJ, "The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research", Psychiatry Res, 28, pp.193~213 (1989)
- Davidson JR, "Major depressive disorder treatment guidelines in America and Europe", J Clin Psychiatry, 71(1), pp.04~ (2010)
- Lin CH, "Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study", J Clin Psychopharmacol, 31, pp.563~568 (2011)
- Gao K, "Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review", J Clin Psychiatry, 67, pp.1327~1340 (2006)
- Yamashita H, "Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults", Am J Geriatr Psychiatry, 13, pp.377~384 (2005)
- raclopride positron emission tomography study, "Am J Psychiatry", 2006, 1594~1602
- Reynolds GP, "Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients", Am J Psychiatry, 163, pp.1826~1829 (2006)
- Thase ME, "What role do atypical antipsychotic drugs have in treatment-resistant depression", J Clin Psychiatry, 63, pp.95~103 (2002)
- Miller DD, "Atypical antipsychotics: sleep, sedation, and efficacy", Prim Care Companion J Clin Psychiatry, 6, pp.3~7 (2004)
- Landolt HP, "Antagonism of serotonergic 5-HT2A", 2C receptors: mutual improvement of sleep, cognition and mood, 2009, pp.29, 1795~1809